Phase 1 Study Evaluates HCB301 in Advanced Solid Tumors and Refractory cHL

FBD Biologics is assessing the safety, pharmacokinetics, and preliminary efficacy of HCB301 administered via IV across escalating doses (0.3 to 15.0 mg/kg) in patients with advanced solid tumors or relapsed/refractory classical Hodgkin lymphoma. The trial aims to establish an effective dose while monitoring for potential adverse effects in subjects ineligible for standard therapy.